Corrigendum to “SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy”
Year: 2019
Type: erratum
Abstract: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing erapy" [1], the second author, Dr. Ballman, was paid by Lilly and only recently realized that gemcitabine is a Lilly product and apologizes for not declaring this sooner.
Source: Sarcoma
DOI: 10.1155/2019/7608743
Institutions: Massachusetts General Hospital, Weill Cornell Medicine, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Memorial Sloan Kettering Cancer Center, University of Michigan, U-M Rogel Cancer Center, Dana-Farber Cancer Institute, Mayo Clinic, The Ohio State University Wexner Medical Center, Michigan Medicine, Cancer Research And Biostatistics, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $820
OpenAlex ID: W2989459236